Biotechnology - Rare diseases, UK, Women's Health

Filter

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

27-11-2014

The UK National Institute for Health and Care Excellence (NICE) has today issued final draft guidance…

Alexion PharmaceuticalsBiotechnologyPricingRare diseasesRegulationSolirisUK

NICE draft guidance recommends Alexion’s Soliris for very rare life-threatening blood disorder

NICE draft guidance recommends Alexion’s Soliris for very rare life-threatening blood disorder

04-09-2014

A drug to treat a very rare blood disorder affecting around 200 people in England has been recommended…

Alexion PharmaceuticalsBiotechnologyHematologyPricingRare diseasesRegulationSolirisUK

UK’s BIA finds government unwilling to set price cap for orphan disease treatment

UK’s BIA finds government unwilling to set price cap for orphan disease treatment

11-03-2014

The majority of Members of Parliament in the UK believe there should not be a maximum price per patient…

BiotechnologyPoliticsPricingRare diseasesUK

COMPANY SPOTLIGHT

Menarini

Back to top